Furthermore, we demonstrated, based on studies in several other cancers, among which ovarian and cervical cancer, that PP2A dysfunction, due to mutations or cellular PP2A inhibitors, could be an indicator for worse prognosis as well as a predictor for therapeutic outcome in EC. The gene discussed is PTPA; the disease is cervical carcinoma.